Straumann Holding AG (OTCMKTS:SAUHY) Stock Short Interest Report for October

Straumann Holding AG (OTCMKTS:SAUHY) saw a large decrease in short interest during the month of October. As of October 15th, there was short interest totaling 26,983 shares, a decrease of 39.9% from the September 30th total of 44,911 shares. Based on an average trading volume of 255,560 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SAUHY shares. Berenberg Bank raised shares of Straumann to a “strong-buy” rating in a research report on Thursday, September 17th. The Goldman Sachs Group raised Straumann from a “neutral” rating to a “buy” rating in a report on Monday, September 14th. Deutsche Bank Aktiengesellschaft downgraded Straumann from a “buy” rating to a “hold” rating in a research note on Friday, August 21st. Citigroup restated a “sell” rating on shares of Straumann in a report on Wednesday, October 21st. Finally, BMO Capital Markets started coverage on Straumann in a research report on Wednesday, July 8th. They set an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Straumann Stock Up 0.6%

Shares of SAUHY stock opened at $11.79 on Friday. Straumann has a 52-week low of $9.44 and a 52-week high of $13.61. The company has a 50-day simple moving average of $11.42 and a two-hundred day simple moving average of $11.66.

Straumann Company Profile

Straumann Group is a Switzerland-based dental technology company headquartered in Basel. Founded in 1954, the company develops, manufactures and distributes products used in tooth replacement, restorative dentistry and oral tissue regeneration. Its offerings are designed for dental professionals, laboratories and patients across a range of clinical applications.

The company’s portfolio includes dental implants, implant-supported prosthetics, biomaterials for bone and tissue regeneration, orthodontic aligners and digital dentistry solutions.